Columbus Venture Partners

Early-stage life sciences and healthcare deep tech fund managed by Columbus Venture Partners. Constituted on 4 August 2026 and registered with CNMV on 18 September 2026 under number 604; the stored date is registration, not a fundraising close. The filed prospectus sets a EUR100 million target and EUR120 million cap, neither a confirmed closed amount. It invests in Spanish technology transfer and incubation, pre-seed and seed projects in biotechnology, advanced therapies, diagnostics, medical devices, digital health, computational biology, AI applicable to life sciences, and specialised manufacturing, with follow-on capacity. Initial portfolio investments have not been verified.

Fifth life sciences fund managed by Columbus Venture Partners, registered with CNMV on 12 September 2025 under number 545. The stored date is registration, not a verified fundraising close. The filed September 2025 prospectus sets a EUR150 million target and EUR200 million cap across the fund and its parallel vehicles; a June 2026 launch report instead describes a EUR200 million target and possible subscriptions up to EUR220 million. The reviewed sources do not reconcile those terms or prove a closed amount. The strategy backs therapies and industrial technologies in healthcare, including rare diseases, longevity and AI applied to life sciences. The launch report uses Innvierte branding while the current registry retains Columbus Life Sciences Fund V.

Fourth biotechnology and pharmaceutical venture fund, with a EUR150 million close announced in the manager’s dated 14 May2024 release, published on15May. The vehicle was incorporated in2023; incorporation is distinct from the2024 closing. It combines disruptive therapeutics and bioindustrial development, targeting10–12 investments and lifetime company commitments from EUR3 million up to EUR20 million.